SENSEX    40515.93       231.74    |    NIFTY    11935.3       50.80 FAQ    |    Feedback
EQUITIES
DERIVATIVES
IPO
COMMODITIES
Gainers & Losers Value & Volume Toppers 52 Weeks High/Low Advances & Declines
New High-Low
Pre-Session Mid-Session End-Session Other Markets Market Beat Stock Alert
Hot Pursuit Foreign Markets Economy News Corporate News Corporate Results
Detailed Quotes Board of Directors Balance Sheet Profit & Loss Quarterly Results Historical Price
Financial Ratios Company Background Technical Chart
Announcements Book Closure Board Meetings Bonus Issues Rights Issues
De-Listed Shares Name Change Split of Face Value Market Turnover
FII Investments MF Investments ADR Prices World Indices
Forthcoming IPOs
Open IPOs
Closed IPOs
New Listing
Basis Of Allotment Draft Prospectus New Issue Monitor
Get Quotes
Gainers
Losers
Value Toppers Advances & Declines Ticker Spot
Ticker Futures Closing Price Technical Chart Commodity News MCX Currency Futures
Get Quotes NIFTY Futures Top Traded Value Top Quantity Most Active Contracts
FII Statistics Daily Settlement Price List of Underlyings Put Call Ratio Derivative Summary
All Index Futures Top Gainers Top Losers Most Active Put Most Active Call
Highest in OI Lowest in OI Increase in OI Decrease in OI
Hot Pursuit
Scrips, which has significant changes during the market hours for last one week.
Wockhardt tumbles as Q2 net loss widens
08-Nov-19   13:21 Hrs IST

The pharmaceutical company announced its Q2 earnings after market hours yesterday. Wockhardt was trading 3.13% lower at Rs 291.4.

Net sales for the period under review dropped 28.7% to Rs 802.18 crore. Revenue expenditure on R&D during Q2 FY2020 amounted to Rs 60 crore (7.4% of sales) as against Rs 82 crore (7.3% of sales) for Q2 FY2019.

The company reported the business performance of the company during the quarter ended 30 September 2019 remained steady. However, H1FY20 EBITDA showed an improvement from Rs 81 crore to Rs 99 crore over previous year.

The company's US business declined 22% and stood at Rs 145 crore in Q2FY20 as compared to Rs 186 crore in Q2FY19. US business contributed 18% of the global revenue.

UK business during the quarter stood at Rs 223 crore in Q2FY20 (PY Rs 251 crore). UK business contributed about 28% of global revenue.

India business stood at Rs 227 crore in Q2FY20 as compared to Rs 455 crore in Q2FY19. The de-growth is mainly on account of lower sales in quality generics division and in some of the therapeutic areas. India business contributed 28% of the global revenue.

During the half year ended 30th September 2019, the company repaid Rs 408 crore towards various long term debt obligations as per schedule. Total long term outstanding debts as on 30th September 2019 was Rs 2,098 crore as compared to Rs 2,789 crore as on 30th September 2018 and Rs 2,469 crore as on 31st March, 2019. Gross debt-equity ratio as on 30th September 2019 stood at 0.94.

Wockhardt has surged 21.78% in last month as compared to a 10.38% rise in Nifty Pharma index.

Wockhardt is a research based global pharmaceutical and biotech company.

Powered by Capital Market - Live News

Currencies
Currency EUR GBP INR USD
Europe (EUR) 1.00 0.86 78.86 1.10
United Kingdom (GBP) 1.17 1.00 92.08 1.29
India (INR) 0.01 0.01 1.00 0.01
United States (USD) 0.91 0.78 71.38 1.00
Commodities << ALL Commodities
GOLDAHMD37931-165
SILVERAHMD44071-252
CRUDEOILMUMBAI413949
COPPERMUMBAI445.50.50
 Market News << ALL News
   Disclaimer   |   BSE Disclosure  |   Privacy Policy   |   Investor Protection   |   Inactive Account
Feedback   |   PMLA Policy   |   Risk Management Policy   |   Insider Trading   
  
   Investor Grivenances   |   Investor Complaints   |   Rules And Regulations   |   Broker Norms   |   Terms of Use SEBI Registration No : INZ000267132   |   BSE Clearing No : 333   
   Copyright © 2011 All rights reserved by Jaysukhlal Jagjivan Stock Broking Pvt.Ltd Designed, Developed & Powered By CMOTS INFOTECH (ISO 9001:2015 certified)